NASDAQ:ACET Adicet Bio (ACET) Stock Price, News & Analysis $0.83 -0.02 (-2.33%) Closing price 04:00 PM EasternExtended Trading$0.86 +0.03 (+3.59%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adicet Bio Stock (NASDAQ:ACET) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adicet Bio alerts:Sign Up Key Stats Today's Range$0.82▼$0.8650-Day Range$0.76▼$1.0352-Week Range$0.74▼$2.43Volume152,101 shsAverage Volume819,565 shsMarket Capitalization$68.65 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingModerate Buy Company OverviewAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Read More… Remove Ads Adicet Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreACET MarketRank™: Adicet Bio scored higher than 67% of companies evaluated by MarketBeat, and ranked 334th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAdicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAdicet Bio has only been the subject of 3 research reports in the past 90 days.Read more about Adicet Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($1.39) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adicet Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.25% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently decreased by 9.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth.Read more about Adicet Bio's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.25% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adicet Bio has recently decreased by 9.87%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.79 News SentimentAdicet Bio has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adicet Bio this week, compared to 2 articles on an average week.Search Interest7 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows4 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have not sold or bought any company stock.Percentage Held by Insiders19.10% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.89% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adicet Bio's insider trading history. Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Stock News HeadlinesAdicet Bio's (ACET) Buy Rating Reiterated at GuggenheimMarch 24, 2025 | americanbankingnews.comAdicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…March 28, 2025 | Paradigm Press (Ad)Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal yearMarch 14, 2025 | investing.comTruist Financial Reaffirms Their Buy Rating on Adicet Bio (ACET)March 10, 2025 | markets.businessinsider.comAdicet Bio reports Q4 EPS (32c), consensus (35c)March 6, 2025 | markets.businessinsider.comAdicet Bio files $250M mixed securities shelfMarch 6, 2025 | markets.businessinsider.comAdicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 6, 2025 | businesswire.comSee More Headlines ACET Stock Analysis - Frequently Asked Questions How have ACET shares performed this year? Adicet Bio's stock was trading at $0.9620 at the start of the year. Since then, ACET shares have decreased by 13.2% and is now trading at $0.8350. View the best growth stocks for 2025 here. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) issued its quarterly earnings results on Thursday, March, 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. Who are Adicet Bio's major shareholders? Adicet Bio's top institutional shareholders include Tang Capital Management LLC (9.89%), Millennium Management LLC (2.20%), Bridgeway Capital Management LLC (1.25%) and Regeneron Pharmaceuticals Inc. (1.17%). Insiders that own company stock include Orbimed Advisors Llc, Don Healey, Francesco Galimi, Chen Schor, Blake Aftab and Steve Dubin. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adicet Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings3/06/2025Today3/28/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors Current SymbolNASDAQ:ACET CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+798.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.85% Return on Assets-46.45% Debt Debt-to-Equity RatioN/A Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$24.99 million Price / Sales2.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.43 per share Price / Book0.34Miscellaneous Outstanding Shares82,686,000Free Float66,662,000Market Cap$69.04 million OptionableOptionable Beta1.97 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ACET) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adicet Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.